Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ranjana Advani

Showing results (1-10 of 128) with videos related to

Pageof 13
Sort By:
Hematology. American Society of Hematology. Education Program|December 14, 2011
Optimal therapy of advanced Hodgkin lymphomaRanjana Advani
Leukemia & Lymphoma|November 4, 2009
Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatmentHolbrook Kohrt, Ranjana Advani
Journal of the National Comprehensive Cancer Network : JNCCN|August 16, 2013
Targeted therapy in relapsed classical hodgkin lymphomaShira Dinner, Ranjana Advani
Critical Reviews in Oncology/Hematology|June 6, 2006
Treatment of mantle cell lymphoma: current approach and future directionsJoshua Brody, Ranjana Advani
Hematology/Oncology Clinics of North America|November 30, 2013
Customized targeted therapy in Hodgkin lymphoma: hype or hope?Catherine Diefenbach, Ranjana Advani
Clinical Lymphoma & Myeloma|April 14, 2009
Targeting CD40 in Waldenström's macroglobulinemiaMark Lee, Ranjana Advani
Hematology. American Society of Hematology. Education Program|December 7, 2024
When should we use it? The role of brentuximab vedotin in 2024Joseph G Schroers-Martin, Ranjana Advani
JCO Oncology Practice|September 12, 2024
Integrating Novel Agents Into the Clinical Management of Classic Hodgkin LymphomaJoseph G Schroers-Martin, Ranjana Advani
Clinical Lymphoma, Myeloma & Leukemia|June 4, 2026
Early Stage Hodgkin Lymphoma-Are We Ready for Novel Agents?Joseph G Schroers-Martin, Ranjana Advani
Expert Review of Anticancer Therapy|September 15, 2010
Risk stratification in extranodal natural killer/T-cell lymphomaHolbrook Kohrt, Mark Lee, Ranjana Advani
Pageof 13

Showing results (1-10 of 128) with videos related to

Sort By:
Pageof 13
Hematology. American Society of Hematology. Education Program|December 14, 2011
Optimal therapy of advanced Hodgkin lymphomaRanjana Advani
Leukemia & Lymphoma|November 4, 2009
Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatmentHolbrook Kohrt, Ranjana Advani
Journal of the National Comprehensive Cancer Network : JNCCN|August 16, 2013
Targeted therapy in relapsed classical hodgkin lymphomaShira Dinner, Ranjana Advani
Critical Reviews in Oncology/Hematology|June 6, 2006
Treatment of mantle cell lymphoma: current approach and future directionsJoshua Brody, Ranjana Advani
Hematology/Oncology Clinics of North America|November 30, 2013
Customized targeted therapy in Hodgkin lymphoma: hype or hope?Catherine Diefenbach, Ranjana Advani
Clinical Lymphoma & Myeloma|April 14, 2009
Targeting CD40 in Waldenström's macroglobulinemiaMark Lee, Ranjana Advani
Hematology. American Society of Hematology. Education Program|December 7, 2024
When should we use it? The role of brentuximab vedotin in 2024Joseph G Schroers-Martin, Ranjana Advani
JCO Oncology Practice|September 12, 2024
Integrating Novel Agents Into the Clinical Management of Classic Hodgkin LymphomaJoseph G Schroers-Martin, Ranjana Advani
Clinical Lymphoma, Myeloma & Leukemia|June 4, 2026
Early Stage Hodgkin Lymphoma-Are We Ready for Novel Agents?Joseph G Schroers-Martin, Ranjana Advani
Expert Review of Anticancer Therapy|September 15, 2010
Risk stratification in extranodal natural killer/T-cell lymphomaHolbrook Kohrt, Mark Lee, Ranjana Advani
Pageof 13